Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05699759 · ClinicalTrials.gov registry record · Phase 1
Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema
A Phase 1 study, sponsored by Michelle Abou-Jaoude.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05699759: Completed Phase 1 study, sponsored by Michelle Abou-Jaoude.
NCT05699759 is a Phase 1 study that has completed, run by Michelle Abou-Jaoude. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05699759, a Phase 1 study, has completed, sponsored by Michelle Abou-Jaoude.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).
Primary Outcome
Central subfield thickness (CST) measured on spectral domain-optical coherence tomography (SD-OCT)
Interventions
- DRUG K8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-01-04 |
| Est. Completion | 2024-06-20 |
| Phase | Phase 1 |
What the finished NCT05699759 record still lists
NCT05699759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which K8 is the first listed.
NCT05699759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05699759 about?
NCT05699759 is a clinical study titled "Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema". This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).
What is the current status of trial NCT05699759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-01-04. Estimated completion is 2024-06-20.
What interventions are being tested in trial NCT05699759?
The interventions under investigation include: K8 (DRUG).
Who is sponsoring clinical trial NCT05699759?
This trial is sponsored by Michelle Abou-Jaoude, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05699759's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI